FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R; The Oncologist, 2007, vol. 12, issue 10, p 1247, ISSN 10837159. ISBN 10837159.
Full Text Resources Located for this Citation